Drug intelligence / Profile preview

OB00X

Development stage: Preclinical
Lead developer: Entos Pharmaceuticals
Modality: Gene Therapies

Overview

OB00X is an investigational gene therapy developed by Entos Pharmaceuticals. It is currently in preclinical development, with its primary indication being age-related disease. The specific mechanism of action, molecular target(s), and detailed modality characteristics have not been publicly disclosed as of the latest available update. The drug represents a novel approach within the field of gene therapy for conditions associated with aging[1][8].

Beyond the preview

Go deeper on OB00X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OB00X.

Explore the full profile